Cardiac safety of liposomal anthracyclines
- First Online:
- Cite this article as:
- Batist, G. Cardiovasc Toxicol (2007) 7: 72. doi:10.1007/s12012-007-0014-4
- 133 Downloads
Anthracyclines remain amongst the most active therapeutic agents for breast cancer treatment. Rather than being supplanted by novel targeted agents, they are being combined with them in various schedules. Furthermore, anthracyclines themselves are still being studied, with increasing biological understanding of their biological activity and molecular targets. A cardiac safe formulation of doxorubicin opens a number of interesting therapeutic opportunities. Liposomal doxorubicins appear to provide this opportunity.